Highly Aggregated Antibody Therapeutics Can Enhance the in Vitro Innate and Late-stage T-cell Immune Responses
Open Access
- 20 July 2012
- journal article
- Published by Elsevier BV in Journal of Biological Chemistry
- Vol. 287 (30), 25266-25279
- https://doi.org/10.1074/jbc.m111.330902
Abstract
No abstract availableKeywords
This publication has 67 references indexed in Scilit:
- Immunogenicity of Therapeutic Proteins: The Use of Animal ModelsPharmaceutical Research, 2011
- Classification and Characterization of Therapeutic Antibody AggregatesOnline Journal of Public Health Informatics, 2011
- Chemical Modifications in Therapeutic Protein Aggregates Generated under Different Stress ConditionsJournal of Biological Chemistry, 2011
- Strategies for the Assessment of Protein Aggregates in Pharmaceutical Biotech Product DevelopmentPharmaceutical Research, 2010
- An Industry Perspective on the Monitoring of Subvisible Particles as a Quality Attribute for Protein TherapeuticsJournal of Pharmaceutical Sciences, 2010
- Assessment of the immunogenicity of different interferon beta-1a formulations using ex vivo T-cell assaysJournal of Pharmaceutical and Biomedical Analysis, 2007
- Effects of protein aggregates: An immunologic perspectiveThe AAPS Journal, 2006
- Interleukin‐10 secreted by B‐1 cells modulates the phagocytic activity of murine macrophages in vitroImmunology, 2004
- The Role of Pharmacokinetics in the Development of Biotechnologically Derived AgentsClinical Pharmacokinetics, 1992
- Effects of tunicamycin on preimplantation mouse embryos: Prevention of molecular differentiation during blastocyst formationDevelopmental Biology, 1985